Loading...
XKRX001360
Market cap101mUSD
Jan 09, Last price  
1,582.00KRW
1D
-1.06%
1Q
-12.40%
Jan 2017
-58.67%
Name

Samsung Pharm Co Ltd

Chart & Performance

D1W1MN
XKRX:001360 chart
P/E
—
P/S
2.87
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
7.72%
Rev. gr., 5y
2.25%
Revenues
51.96b
+0.24%
32,802,727,00033,236,504,00037,057,787,00039,243,911,00044,078,652,92047,285,858,94046,920,574,89030,287,781,51042,164,637,26048,223,429,86041,919,468,82046,483,649,02044,566,363,21048,269,172,24054,901,130,22051,832,233,85051,955,037,960
Net income
-24.81b
L-32.86%
-2,356,850,000634,209,0001,316,511,000-906,230,000-1,748,024,980-3,132,252,050-18,488,789,520-23,748,181,000-994,386,000-21,617,603,000-7,539,887,910-2,075,705,8306,885,173,790-63,764,012,920-62,678,093,540-36,953,663,440-24,812,021,760
CFO
-27.66b
L+1,344.79%
-1,492,388,0001,080,371,000-3,653,848,000-4,269,383,000-1,647,520,000-11,126,576,090603,654,480-13,583,335,010-4,204,949,290-9,941,381,0805,539,090,000-6,520,527,840-2,434,316,720-2,553,234,930-7,162,788,010-1,914,279,990-27,657,307,943
Earnings
Mar 11, 2025

Profile

SAMSUNG PHARM. Co., LTD. manufactures and sells pharmaceutical products in South Korea. It offers prescription medicines, such as anticancer immunotherapy, antipyretic analgestic and antiinflammatory, antiobesity, hypotensive, antiarteriosclerotic, digestive organs, antophlegms, enzymes, ostepoposis, and transfusion agents, as well as skeletal muscle relaxants, anti-spastic, mixed vitamins, antibiotics, and others. The company also provides medicines for digestive system, medicines for liver disorder, medicines for circulation system, cold medicines, nutritional supplements, health tonics, and others, as well as vitamins and energy drinks, and functional foods. The company was founded in 1929 and is based in Hwaseong-si, South Korea.
URL
https://www.sspharm.co.kr/new/main/main.php
IPO date
Jul 04, 1975
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
51,955,038
0.24%
51,832,234
-5.59%
Cost of revenue
64,589,329
60,225,262
Unusual Expense (Income)
NOPBT
(12,634,291)
(8,393,029)
NOPBT Margin
Operating Taxes
1,137,105
11,860,632
Tax Rate
NOPAT
(13,771,396)
(20,253,661)
Net income
(24,812,022)
-32.86%
(36,953,663)
-41.04%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
493,668
1,279,507
Long-term debt
697,304
2,408,268
Deferred revenue
238,429
324,541
Other long-term liabilities
104,889
46,662
Net debt
(35,313,546)
(52,156,376)
Cash flow
Cash from operating activities
(27,657,308)
(1,914,280)
CAPEX
(12,779,783)
(3,034,827)
Cash from investing activities
(2,636,479)
12,824,188
Cash from financing activities
(1,422,820)
(1,004,704)
FCF
(25,495,904)
(10,759,750)
Balance
Cash
4,281,308
55,986,098
Long term investments
32,223,210
(141,947)
Excess cash
33,906,766
53,252,539
Stockholders' equity
(56,807,177)
(31,445,856)
Invested Capital
135,330,528
136,379,275
ROIC
ROCE
EV
Common stock shares outstanding
74,326
74,393
Price
1,962.37
-26.91%
2,685.00
-45.48%
Market cap
145,854,502
-26.98%
199,745,337
-44.85%
EV
110,540,956
147,588,961
EBITDA
(10,720,540)
(5,385,604)
EV/EBITDA
Interest
73,369
111,091
Interest/NOPBT